Blog post by Ron Hollander.

The International Neuroendocrine Cancer Alliance (INCA) held its annual  Summit and Member meeting in Oxford, England. The assembled representatives from NET groups in 18 nations focused on ways to spread awareness, assist NET groups, and support research for NET patients worldwide. 

INCA summit Oxford

(L-R) INCA Secretary Jo Grey (UK) – Association for Multiple Endocrine Neoplasia Disorders (AMEND); CFCF Funded Researcher Tim Meyer, MD, PhD – UCL Cancer Institute, University College London; INCA President Teodora Kolarova (Bulgaria) – APOZ & Friends; Ron Hollander – CFCF Executive Director; Josh Mailman – President of NorCal CarciNET Community; Yoshiyuki Majima (Japan) – PanCan

Among the speakers were;
Recent CFCF Immunotherapy (IMT)  investigator Tim Meyer, MD from UCL Cancer Institute, University College London, who described his research and its relationship to a possible pathway for clinical trials.
Josh Mailman, President of NorCal CarciNET, provided an overview of the significance of Orphan Drug designation, and the group focused considerable attention on the difficulties that patients in many countries are having with respect to PRRT access.
CFCF Executive Director (and INCA President-elect) Ron Hollander provided an overview of NET research, focusing on immunotherapy and the exciting potential of our current initiative.